Patient selection for CGRP-targeted monoclonal antibody prevention
Key messages
- Access to migraine prevention treatment is influenced by sociodemographic factors and less than a third of people requiring treatment are receiving it.
- Empirical research is required to improve access to preventative treatments and to inform the revision of the AHS Position Statement.